Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB Cause Intervertebral disc protrusion? 219 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 219 reports of Intervertebral disc protrusion have been filed in association with NATALIZUMAB (TYRUKO). This represents 0.3% of all adverse event reports for NATALIZUMAB.

219
Reports of Intervertebral disc protrusion with NATALIZUMAB
0.3%
of all NATALIZUMAB reports
0
Deaths
123
Hospitalizations

How Dangerous Is Intervertebral disc protrusion From NATALIZUMAB?

Of the 219 reports, 123 (56.2%) required hospitalization, and 2 (0.9%) were considered life-threatening.

Is Intervertebral disc protrusion Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 219 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB Cause?

Multiple sclerosis relapse (6,478) Fatigue (4,456) Multiple sclerosis (4,078) Memory impairment (3,024) Malaise (2,523) Fall (2,481) Headache (2,476) Gait disturbance (2,427) Prescribed underdose (2,162) Maternal exposure during pregnancy (1,948)

What Other Drugs Cause Intervertebral disc protrusion?

ADALIMUMAB (2,760) ETANERCEPT (751) METHOTREXATE (648) SODIUM OXYBATE (427) PREGABALIN (415) TOFACITINIB (393) UPADACITINIB (384) INTERFERON BETA-1A (295) PREDNISONE (285) SECUKINUMAB (268)

Which NATALIZUMAB Alternatives Have Lower Intervertebral disc protrusion Risk?

NATALIZUMAB vs NATALIZUMAB-SZTN NATALIZUMAB vs NATAMYCIN NATALIZUMAB vs NATEGLINIDE NATALIZUMAB vs NAVITOCLAX NATALIZUMAB vs NAXITAMAB-GQGK

Related Pages

NATALIZUMAB Full Profile All Intervertebral disc protrusion Reports All Drugs Causing Intervertebral disc protrusion NATALIZUMAB Demographics